Figure 7.

Assessment of the antiangiogenic response to integrin-targeted fumagillin nanoparticles with α₅β₁(α_νβ₃)-targeted MR contrast agent. Top: the extent of neovascularity was quantified by calculating the amount of signal enhancement in the tumor periphery. α₅β₁(α_νβ₃)-targeted fumagillin nanoparticles reduced peripheral tumor neovascularity relative to control (P<0.05, n=5). α_νβ₃-targeted fumagillin nanoparticles had no significant effect on angiogenesis, compared to control. Bottom: the effect of α₅β₁(α_νβ₃)-targeted fumagillin nanoparticles on tumor neovascular morphology is clearly apparent on 3D reconstructions of MR signal enhancement. Tumor volume is outlined in gray; contrast-enhanced pixels are blue.